Symptom persistence and biomarkers in post-COVID-19/chronic fatigue syndrome - results from a prospective observational cohort

Introduction: Post-COVID-19 syndrome (PCS) is characterized by a wide range of symptoms, predominantly fatigue and exertional intolerance. While disease courses during the first year post infection have been repeatedly described, little is known about long-term health consequences. Methods: We assessed symptom severity and various biomarkers at three time points post infection (3-8 months (mo), 9-16mo, 17-20mo) in 106 PCS patients with moderate to severe fatigue and exertional intolerance. A subset of patients fulfilled diagnostic criteria of myalgic encephalomyelitis/chronic fatigue syndrome (PCS-ME/CFS) based on the Canadian Consensus Criteria. Results: While PCS-ME/CFS patients showed persisting symptom severity and disability up to 20mo post infection, PCS patients reported an overall health improvement. Inflammatory biomarkers equally decreased in both groups. Lower hand grip force at onset correlated with symptom persistence especially in PCS-ME/CFS. Discussion: Debilitating PCS may persist beyond 20mo post infection, particularly in patients fulfilling diagnostic criteria for ME/CFS.

[1]  Quanzhen Li,et al.  Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms , 2022, European Respiratory Journal.

[2]  Mehrbod Vakhshoori,et al.  Hypophosphatemia in Coronavirus Disease 2019 (COVID-19), Complications, and Considerations: A Systematic Review , 2022, BioMed research international.

[3]  F. Paulus,et al.  Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity , 2022, Frontiers in Immunology.

[4]  Mark S. Anderson,et al.  Studying severe long COVID to understand post-infectious disorders beyond COVID-19 , 2022, Nature Medicine.

[5]  P. Ravaud,et al.  Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort , 2022, Nature Communications.

[6]  F. Paul,et al.  Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) , 2022, Journal of translational medicine.

[7]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[8]  S. Kent,et al.  Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.

[9]  Ruoran Wang,et al.  Hypophosphatemia at Admission is Associated with Increased Mortality in COVID-19 Patients , 2021, International journal of general medicine.

[10]  P. Edison,et al.  Long covid—mechanisms, risk factors, and management , 2021, BMJ.

[11]  F. Dioguardi,et al.  Serum Metabolic Profile in Patients With Long-Covid (PASC) Syndrome: Clinical Implications , 2021, Frontiers in Medicine.

[12]  U. Merle,et al.  Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Scheibenbogen,et al.  Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany , 2021, Medicina.

[14]  S. Rosenkranz,et al.  Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study , 2021, The Lancet Regional Health - Europe.

[15]  C. Scheibenbogen,et al.  European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe , 2021, Medicina.

[16]  C. Scheibenbogen,et al.  Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS , 2021, Journal of translational medicine.

[17]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[18]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[19]  H. Volk,et al.  Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany: a first analysis of a prospective observational study , 2021, medRxiv.

[20]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[21]  M. Spruit,et al.  Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? , 2020, ERJ Open Research.

[22]  Cheryl A. Glass,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2019, Adult-Gerontology Practice Guidelines.

[23]  L. Jason,et al.  A Brief Questionnaire to Assess Post-Exertional Malaise , 2018, Diagnostics.

[24]  C. Scheibenbogen,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease. , 2018, Autoimmunity reviews.

[25]  I. Mena,et al.  Myalgic encephalomyelitis: International Consensus Criteria , 2011, Journal of internal medicine.

[26]  C. Meisel,et al.  Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome , 2016, Brain, Behavior, and Immunity.

[27]  L. Jason,et al.  Defining Essential Features of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome , 2015, Journal Of Human Behavior In The Social Environment.

[28]  C. Jackson,et al.  The Chalder Fatigue Scale (CFQ 11). , 2015, Occupational medicine.

[29]  L. Jason,et al.  Cognitive impairments associated with CFS and POTS , 2013, Front. Physiol..

[30]  J. Mandrekar,et al.  COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. , 2012, Mayo Clinic proceedings.

[31]  C. Dorn,et al.  Determination of total interleukin-8 in whole blood after cell lysis. , 2000, Clinical chemistry.

[32]  R. Morriss,et al.  Exploring the validity of the Chalder Fatigue scale in chronic fatigue syndrome. , 1998, Journal of psychosomatic research.

[33]  D. Bell The Doctor's Guide To Chronic Fatigue Syndrome: Understanding, Treating,And Living With Cfids , 1994 .

[34]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .